Biologics CDMO Market Expansion to $105.32 Billion by 2029: Key Drivers and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the biologics cdmo market from 2025–2034 with trusted insights from The Business Research Company

What Is The Base Market Size For The Biologics CDMO Market Today And What Will It Reach By 2029?

The pulmonary or respiratory drug delivery market size has experienced strong growth in recent years. It is anticipated to increase from $69.83 billion in 2024 to $75.67 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.4%. The expansion observed in prior periods can be attributed to the rising occurrence of asthma, increased acceptance of sophisticated inhalation devices, a global increase in healthcare expenditure, enhanced public understanding of respiratory illnesses, and the growing incidence of allergic conditions.

The pulmonary or respiratory drug delivery market size is anticipated to undergo significant expansion over the coming years, with projections indicating it will attain a value of $105.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.6%. This growth during the forecast period is primarily fueled by the increasing demand for personalized medicine, a rising incidence of chronic respiratory diseases, a heightened emphasis on telemedicine, growing investments in healthcare infrastructure, and the expansion of e-commerce channels for pharmaceutical products. Noteworthy trends predicted for this period encompass progress in particle engineering, the development of advanced nebulizers, the creation of liposomal formulations, advancements in computational fluid dynamics, and the innovation of smart inhalers.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What Factors Are Boosting The Biologics CDMO Market?

The growing occurrence of pneumonia is anticipated to boost the expansion of the pulmonary or respiratory drug delivery market in the future. Pneumonia, a lung infection, results in the inflammation of air sacs that can become filled with fluid or pus, manifesting as symptoms such as coughing, fever, and labored breathing. The rising incidence of pneumonia is linked to factors including an aging global population, compromised immune systems, other respiratory infections, environmental air pollution, smoking habits, and the emergence of bacteria resistant to antibiotics. For individuals suffering from pneumonia, pulmonary or respiratory drug delivery offers assistance by directly introducing medications like antibiotics, bronchodilators, or anti-inflammatory agents into the lungs. This method allows for more rapid and efficient treatment, helping to relieve symptoms, decrease inflammation, eliminate infections, and enhance overall respiratory function, thereby promoting recovery and averting complications. An example highlighting this trend is seen in November 2023, where data from the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, indicated a significant increase in pneumonia cases in Kenya, reaching 793,864 during 2022/2023. Consequently, the growing incidence of pneumonia acts as a key driver for the pulmonary or respiratory drug delivery market.

How Is The Biologics CDMO Market Categorized By Application, Type, And Region?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

How Are Technological Trends Affecting The Biologics CDMO Market Growth?

Key players within the pulmonary or respiratory drug delivery market are prioritizing technological innovations, such as sophisticated drug delivery systems, to enhance treatment effectiveness and improve patient adherence. These advanced drug delivery systems are cutting-edge technologies designed to refine the precise targeting and controlled release of therapeutic compounds, thereby elevating drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company that manufactures generic and branded medicines, and Kindeva Drug Delivery L.P., a US-based company offering drug delivery solutions, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol that received approval from the Food and Drug Administration, a US-based government agency. This product represents the first generic version of AstraZeneca’s Symbicort and is a metered-dose inhaler that combines budesonide and formoterol for the treatment of asthma and chronic obstructive pulmonary disease. It is supplied in two strengths, 80 micrograms and 160 micrograms, each containing 4.5 micrograms of formoterol.

Who Are The Global Leaders Steering The Biologics CDMO Market Forward?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Biologics CDMO Market?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Browse Through More Reports Similar to the Global Biologics CDMO Market 2025, By The Business Research Company

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Idiopathic Pulmonary Fibrosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795